Sell or avoid the stock. The ~$1.2M raise is a drop in the bucket for a company facing a near-term NYSE delisting deadline (June 11, 2026), a ~$9.8M stockholders' deficit, and a massive existing warrant overhang. The concurrent private placement adds up to 10.2M common warrants at the same strike as the offering, creating a multi-year overhang. Even if the Phase 3 pancreatic cancer trial succeeds, the dilution path makes the risk/reward unacceptable for common equity holders. Monitor for any reverse-split or restructuring announcements as delisting approaches.
Price Chart
Executive Summary
AIM ImmunoTech is conducting a best-efforts registered direct offering of 2,554,119 shares at $0.5189/share (~$1.33M gross), coupled with a concurrent private placement of 771,503 unregistered shares, pre-funded warrants for 1,782,616 shares at $0.001, and common warrants for 10,216,476 shares at $0.5189. The net proceeds of ~$1.2M are intended for a Phase 3 pancreatic cancer trial, clinical drug supply, and working capital. The company is not in compliance with the NYSE American's stockholders' equity rule and faces potential delisting if it cannot regain compliance by June 11, 2026. The massive potential dilution from the private placement warrants (up to ~10.2M additional shares) and the company's existing warrant overhang (~40M+ shares issuable) creates severe downward pressure on the stock, outweighing the modest capital infusion.
Key Facts
- Offering 2,554,119 shares of common stock at $0.5189/share for gross proceeds of ~$1.33 million
- Estimates net proceeds of ~$1.2 million after placement agent fees and expenses
- Concurrent private placement includes 771,503 unregistered shares, pre-funded warrants for 1,782,616 shares, and common warrants for 10,216,476 shares
- Common warrants have an exercise price of $0.5189/share and expire 5 years after stockholder approval
- Pre-funded warrants have an exercise price of $0.001/share and do not expire until exercised in full
- Existing warrant overhang: ~40M+ shares issuable from multiple warrant series (Class E through I, plus placement agent warrants)
- Company is not in compliance with NYSE American's $6M minimum stockholders' equity rule; must regain compliance by June 11, 2026
- As of Dec 31, 2025, stockholders' deficit was ~$9.8 million
- Offering is best-efforts with no minimum raise requirement — proceeds may be substantially less than maximum
- Immediate dilution of ~$0.38/share for investors buying at the offering price, based on as-adjusted net tangible book value of $0.14/share
Financial Impact
Immediate equity dilution of ~10.5% from the registered offering alone, plus massive potential dilution from the concurrent private placement warrants (10,216,476 common warrants) and existing warrant overhang (~40M+ shares). Net proceeds of ~$1.2M provide only limited runway for a cash-burning pre-revenue biotech.
Risk Factors
- Potential delisting from NYSE American if stockholders' equity is not restored to $6M by June 11, 2026
- Severe dilution from existing and new warrant overhang (~40M+ existing + 10.2M new common warrants + 1.8M pre-funded warrants + 771K unregistered shares)
- Best-efforts offering may raise far less than the $1.2M target, leaving the company undercapitalized
- No approved products in the US; Ampligen is only approved in Argentina for chronic fatigue syndrome
- Going-concern risk highlighted in the auditor's report on the 2025 financial statements
- Lack of a trading market for the new common warrants limits liquidity and creates price discovery risk
- Stock price already near an all-time low (~$0.52), vulnerable to further decline from dilution and delisting risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-028088 |
| Document: 0001493152-26-028088-index-headers.html | 0001493152-26-028088 |
| Document: 0001493152-26-028088-index.html | 0001493152-26-028088 |
| Document: 0001493152-26-028088.txt | 0001493152-26-028088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers